industri
countri
maintain
surveil
program
monitor
transmiss
infect
blood
donat
revis
approach
methodolog
risk
assess
new
threat
emerg
comparison
program
unit
state
canada
franc
uk
australia
indic
similar
function
although
structur
blood
program
vari
extent
natur
formal
tie
public
health
emerg
hiv
late
earli
key
recogn
surveil
system
specif
blood
transfus
essenti
henc
industri
countri
monitor
transfusiontransmiss
infect
donor
evalu
impact
new
test
predon
screen
strategi
emerg
infect
sinc
hiv
differ
transmiss
pathway
challeng
blood
program
draw
upon
resourc
rapid
effect
respons
recognit
origin
focu
sexualdrugrel
risk
hiv
hepat
inadequ
focu
surveil
program
new
emerg
pathogen
fulfil
key
role
risk
assess
polici
formul
precis
natur
activ
vari
countri
structur
blood
program
surveil
system
strateg
focu
blood
program
epidemiolog
diseas
countri
industri
countri
maintain
surveil
program
monitor
transmiss
infect
blood
donat
revis
approach
methodolog
risk
assess
new
threat
emerg
comparison
program
unit
state
canada
franc
uk
australia
indic
similar
function
although
structur
blood
program
vari
extent
natur
formal
tie
public
health
emerg
hiv
late
earli
key
recogn
surveil
system
specif
blood
transfus
essenti
henc
industri
countri
monitor
transfusiontransmiss
infect
donor
evalu
impact
new
test
predon
screen
strategi
emerg
infect
sinc
hiv
differ
transmiss
pathway
challeng
blood
program
draw
upon
resourc
rapid
effect
respons
recognit
origin
focu
sexualdrugrel
risk
hiv
hepat
inadequ
focu
surveil
program
new
emerg
pathogen
fulfil
key
role
risk
assess
polici
formul
precis
natur
activ
vari
countri
structur
blood
program
surveil
system
strateg
focu
blood
program
epidemiolog
diseas
countri
publish
elsevi
inc
ethod
monitor
assess
transfus
transmiss
infect
relat
donor
risk
evalu
emerg
threat
safeti
essenti
henc
blood
program
industri
countri
maintain
surveil
program
monitor
transmiss
infect
safeti
blood
donat
surveil
methodolog
risk
assess
approach
adapt
new
threat
blood
suppli
emerg
surveil
also
provid
monitor
risk
assess
address
divers
interest
physician
counsel
patient
commun
stakehold
interest
valu
safeti
initi
public
health
profession
interest
transmiss
diseas
healthi
popul
countri
develop
surveil
differ
start
point
differ
point
time
trigger
event
differ
rate
differ
structur
blood
program
suit
purpos
thu
countri
program
ident
anoth
divers
program
may
exist
within
specif
countri
comparison
surveil
data
specif
topic
provid
insight
impact
differ
safeti
strategi
comparison
differ
countri
approach
surveil
risk
assess
receiv
littl
attent
literatur
comparison
provid
insight
defin
core
characterist
transmiss
infect
surveil
program
well
describ
potenti
divers
adapt
furthermor
surveil
analys
use
extens
blood
servic
intern
purpos
breadth
research
activ
well
repres
literatur
thu
make
comparison
program
incomplet
without
insid
view
review
compar
exampl
surveil
program
develop
countri
contin
describ
similar
differ
approach
function
applic
also
examin
discuss
factor
shape
develop
program
data
surveil
ultim
deriv
blood
center
underli
structur
blood
program
consider
extent
dictat
qualiti
complet
data
avail
surveil
well
structur
surveil
particular
countri
assum
countri
organ
nation
structur
surveil
effort
section
summar
key
point
differ
countri
understand
impact
surveil
approach
activ
compar
data
summar
tabl
us
blood
system
compos
multipl
independ
licens
blood
collect
agenc
agreement
place
facilit
share
blood
product
area
need
largest
singl
blood
establish
american
red
cross
arc
collect
almost
half
us
blood
suppli
state
rest
collect
separ
independ
commun
center
state
mani
affili
network
call
america
blood
center
abc
addit
blood
suppli
collect
hospit
mani
independ
blood
center
center
potenti
monitor
data
varieti
comput
system
code
practic
coordin
surveil
data
produc
nation
statist
extrem
challeng
unit
state
develop
sever
partial
solut
address
retroviru
epidemiolog
donor
studi
red
establish
fund
nation
institut
health
studi
group
collect
donor
data
differ
blood
center
singl
databas
analysi
facilit
independ
research
center
conduct
safetyrel
studi
donor
survey
merg
data
differ
comput
system
requir
elabor
encrypt
procedur
maintain
anonym
donor
permit
donat
donor
identifi
track
howev
includ
us
donor
could
identifi
unusu
trend
center
involv
studi
although
center
geograph
divers
randomli
select
necessarili
repres
us
blood
suppli
largest
blood
supplier
arc
maintain
epidemiolog
surveil
depart
within
research
develop
divis
provid
larger
databas
transmiss
infect
surveil
gener
consid
repres
nation
trend
everi
donat
made
arc
sinc
although
limit
blood
system
anoth
larg
blood
supplier
multipl
blood
collect
center
sever
us
state
member
abc
also
activ
epidemiolog
surveil
depart
last
decad
red
group
focus
less
nation
surveil
epidemiolog
pathogen
test
expand
new
direct
molecular
surveil
hiv
hepat
c
viru
hcv
hepat
b
viru
hbv
strain
found
blood
donor
studi
emerg
pathogen
intern
blood
safeti
research
project
individu
blood
center
also
particip
research
monitor
epidemiolog
surveil
depart
arc
blood
system
fund
organ
although
also
seek
competit
grant
specif
project
contrast
red
activ
fund
govern
research
contract
us
biovigil
network
fund
govern
agenc
aabb
member
organ
recruit
fundrais
effort
recommend
commiss
enquiri
blood
system
canada
assess
circumst
contribut
transfus
transmiss
hiv
hcv
implement
test
blood
servic
canada
reform
canadian
red
cross
societi
blood
transfus
servic
new
blood
servic
provid
blood
servic
intend
function
arm
length
govern
ensur
independ
clear
line
respons
safeti
blood
suppli
approxim
three
quarter
canada
blood
suppli
collect
distribut
canadian
blood
servic
cb
provinc
territori
one
quarter
collect
distribut
hq
provinc
organ
mostli
use
assay
although
implement
date
may
vari
donor
select
screen
method
also
similar
commun
facilit
organ
crossmembership
variou
committe
also
public
health
represent
frequent
inform
commun
collabor
public
health
gener
initi
specif
purpos
issu
organ
maintain
epidemiolog
program
fund
intern
focu
primarili
intern
inform
requir
format
current
blood
servic
surveil
activ
enhanc
cb
epidemiolog
surveil
depart
fund
increas
staff
reloc
origin
site
toronto
ontario
center
head
offic
ottawa
ontario
organ
develop
databas
suitabl
surveil
purpos
valid
data
extend
far
back
surveil
data
share
organ
gener
compil
nation
data
aftermath
recognit
transfus
risk
hiv
hcv
institut
nation
de
la
transfus
sanguin
int
form
ensur
surveil
transfus
safeti
agenc
independ
etabliss
du
sang
ef
nation
blood
servic
respons
collect
distribut
blood
product
franc
oversea
depart
blood
center
continent
franc
caribbeanguadeloup
martiniqueand
island
indian
ocean
also
independ
blood
center
arm
forc
centr
de
transfus
sanguin
de
ctsa
partnership
int
institut
de
veill
sanitair
inv
nation
agenc
respons
public
health
surveil
formal
ef
ctsa
int
inv
perform
surveil
blood
program
fulli
fund
govern
clearli
differenti
line
respons
partnership
facilit
realtim
share
inform
popul
data
awar
plan
public
health
surveil
activ
collabor
address
emerg
threat
test
blood
donat
conduct
center
nation
refer
center
part
int
sampl
posit
donat
sent
use
test
monitor
assess
safeti
blood
program
supplement
test
includ
routin
addit
test
well
ad
hoc
test
address
specif
safeti
question
donor
databas
suitabl
analysi
maintain
nation
blood
center
ef
addit
surveybas
donor
data
also
collect
databas
access
int
inv
staff
blood
donor
data
origin
collat
work
group
french
blood
transfus
societi
includ
approxim
donat
sinc
data
whole
ef
complet
present
uk
polit
compos
region
devolv
govern
scotland
wale
northern
ireland
england
govern
uk
govern
blood
servic
uk
part
nation
health
servic
nh
publicli
fund
health
care
system
sinc
nh
form
blood
servic
much
longer
histori
region
respect
nation
health
servic
blood
servic
nation
blood
servic
respons
region
surveil
activ
coordin
nation
surveil
address
format
special
transfus
epidemiolog
depart
fund
jointli
nh
blood
transplant
nhsbt
england
northern
wale
health
protect
agenc
hpa
english
nation
bodi
respons
surveil
infecti
diseas
unit
compos
employe
organ
coloc
base
nhsbt
hpa
aggreg
data
report
unit
blood
servic
voluntarili
donat
test
plu
disaggreg
data
posit
donat
marker
enhanc
data
infect
donor
includ
risk
exposur
donat
histori
collect
unit
donor
blood
servic
format
joint
blood
servicehpa
epidemiolog
unit
allow
share
surveil
epidemiolog
expertis
facilit
close
collabor
public
health
access
relev
popul
data
releas
public
report
earli
knowledg
appropri
input
transfus
issu
public
health
surveil
plan
close
collabor
emerg
infecti
diseas
surveil
addit
benefit
transfus
safeti
also
readi
potenti
transfus
surveil
data
benefit
public
health
decis
make
collabor
detail
form
standard
provid
report
diseas
includ
nation
statist
also
done
requir
law
australian
red
cross
blood
servic
henceforth
australian
blood
servic
ab
establish
nation
blood
servic
transfus
servic
previous
manag
individu
state
territori
red
cross
transfus
servic
oper
continu
sinc
ab
respons
collect
process
distribut
blood
product
australia
state
territori
fund
provid
central
deed
agreement
nation
blood
author
australian
feder
govern
bodi
administ
blood
sector
donat
test
consolid
test
center
use
infecti
diseas
screen
assay
australian
stateterritori
govern
manag
public
health
system
includ
surveil
transmiss
infect
addit
australian
govern
requir
statesterritori
report
notifi
diseas
eg
blood
born
arbovirus
form
nation
databas
manag
communic
diseas
network
australia
complex
system
requir
surveil
transfusiontransmiss
diseas
occur
region
stateterritori
public
health
unit
nation
level
communic
diseas
network
australiaan
arm
australian
govern
depart
health
age
ab
structur
mirror
medic
servic
manag
report
nation
chief
medic
offic
stateterritori
respons
liais
public
health
unit
manag
local
issu
ab
also
dedic
nation
surveil
arm
polici
unit
also
report
chief
medic
offic
ab
maintain
singl
nation
comput
system
contain
blood
donat
test
data
onward
limit
donat
data
preexist
stateterritori
comput
system
migrat
nation
system
nation
viral
test
algorithm
place
sinc
support
period
nation
trend
analysi
residu
risk
estim
ab
surveil
feed
within
organ
overarch
donor
product
safeti
committe
chair
nation
medic
specialist
collabor
project
public
health
profession
collabor
risk
assess
nation
centr
hiv
epidemiolog
clinic
research
partial
integr
blood
program
popul
data
achiev
public
blood
donor
data
annual
surveil
report
emerg
hiv
late
recognit
transfus
transmiss
infect
creat
longlast
public
pressur
transfus
safeti
countri
report
import
precipit
factor
reform
blood
servic
countri
canada
franc
furthermor
public
concern
safeti
underscor
import
nation
transfusiontransmiss
diseas
surveil
catalyst
establish
andor
strengthen
surveil
program
countri
describ
report
review
structur
blood
program
identifi
key
point
differ
impact
upon
surveil
number
blood
supplier
interact
public
health
level
independ
monitor
safeti
nation
surveil
key
monitor
safeti
enabl
discern
trend
infect
may
geograph
differenti
blood
supplier
tend
complic
sever
reason
first
confidenti
donor
data
highli
protect
countri
second
inform
technolog
issu
make
combin
data
challeng
third
cost
impedi
produc
nation
surveil
data
requir
creativ
solut
countri
supplier
even
solut
program
like
produc
somewhat
limit
data
surveil
conduct
countri
singl
nation
blood
program
uk
nation
coordin
achiev
largest
blood
supplier
hpa
unit
state
newli
establish
nation
biovigil
network
coordin
publicpriv
partnership
govern
agenc
cdc
transfus
medicin
profession
associ
aabb
approach
limit
level
interpret
possibl
nevertheless
achiev
primari
goal
monitor
nation
level
nation
blood
supplier
hand
collat
donor
transmiss
diseas
data
singl
databas
real
time
monitor
differ
demograph
geograph
level
thu
countri
singl
nation
blood
supplier
substanti
advantag
coordin
analyz
nation
data
noteworthi
howev
nation
system
although
complet
within
countri
may
far
smaller
independ
system
within
countri
unit
state
intern
benchmark
perform
data
includ
transfusiontransmiss
infect
marker
rate
facilit
sever
industri
allianc
ab
cb
arc
nhsbt
member
allianc
blood
oper
also
includ
abc
european
blood
allianc
ef
member
european
blood
allianc
thu
allianc
blood
oper
member
ab
found
member
asia
pacif
blood
network
provid
focu
asiapacif
region
surveil
activ
global
network
creat
allianc
provid
effici
forum
rapid
informationresourc
share
includ
surveil
establish
emerg
transfusiontransmiss
diseas
threat
recent
exampl
underscor
valu
includ
collabor
influenza
pandem
optim
blood
servic
respons
develop
dengu
manag
white
paper
provid
polici
guidanc
asia
pacif
blood
network
member
countri
report
found
interact
public
health
depart
essenti
focu
expand
hiv
hcv
hbv
rang
emerg
pathogen
depend
upon
interact
increas
countri
formal
tie
public
health
depart
gener
initi
interact
specif
purpos
clear
need
identifi
countri
uk
franc
closer
associ
public
health
easier
access
public
health
data
better
opportun
stay
current
public
health
plan
clearli
defin
portal
collabor
address
emerg
pathogen
furthermor
surveil
blood
program
parallel
interest
public
health
surveil
larg
popul
test
activ
oppos
passiv
report
monitor
well
transfus
transmiss
prevent
countri
review
report
donor
test
posit
transmiss
diseas
public
health
author
via
usual
report
channel
requir
law
countri
formal
tie
may
greater
potenti
assist
public
health
surveil
countri
fulli
intern
fund
surveil
program
larg
reflect
focu
independ
necessari
rather
depend
fund
agenc
give
transfus
project
prioriti
notabl
except
unit
state
blood
oper
fund
program
supplement
competit
fund
recent
donor
hemovigil
compon
us
biovigil
network
attempt
implement
fulli
coordin
nation
donor
surveil
system
fund
sever
sourc
strongest
indic
safeti
countri
blood
suppli
rest
extent
transfus
transmiss
infecti
agent
occur
countri
report
system
place
detect
complic
aris
transfus
includ
transmiss
diseas
section
describ
approach
suspect
transfusiontransmit
infect
tti
report
blood
supplier
soon
identifi
blood
supplier
initi
traceback
investig
unit
receiv
recipi
identifi
blood
center
attempt
contact
donor
unit
test
lookback
posit
donat
initi
review
previou
donat
implic
donor
hospit
unit
releas
notifi
contact
recipi
test
blood
servic
lookbacktraceback
system
place
monitor
give
indic
frequenc
tti
transfusiontransmit
infect
rare
gener
identifi
test
implement
infect
rare
identifi
test
establish
transfus
account
small
proport
gener
popul
infect
hemovigil
program
captur
wide
rang
transfus
reaction
although
tti
best
captur
directli
report
blood
supplier
establish
french
nation
hemovigil
program
earliest
nation
surveil
program
serv
model
countri
establish
program
seriou
hazard
transfus
program
establish
ukwid
report
system
patient
transfus
event
although
surveil
tti
exist
uk
epidemiolog
unit
respons
coordin
data
arc
formal
hemovigil
program
place
mani
year
canada
hemovigil
began
pilot
project
involv
provinc
nation
report
place
sinc
australia
variou
state
territori
differ
form
advers
event
report
track
differ
stage
report
capac
nation
blood
author
gather
togeth
report
transfus
incid
state
territori
establish
report
voluntari
nation
hemovigil
program
princip
limit
assess
safeti
tti
directli
difficulti
confirm
sourc
infect
blood
donat
also
potenti
infect
miss
confirm
transfus
transmiss
diseas
base
rang
data
includ
patient
symptom
indic
new
infect
pretransfus
patient
sampl
neg
marker
posit
patient
sampl
posttransfus
trace
donor
posit
sampl
genet
sequenc
pathogen
match
donor
recipi
sampl
rare
data
avail
patient
pretransfus
sampl
often
avail
donor
alway
trace
andor
will
provid
sampl
sometim
donor
infect
resolv
followup
test
henc
transfus
transmiss
usual
consid
probabl
possibl
depend
data
avail
less
often
confirm
addit
patient
symptom
may
mild
may
alway
attribut
infect
patient
may
die
underli
patholog
without
detect
infect
gener
consid
infect
report
hospit
report
blood
center
potenti
transfus
transmiss
may
lack
requisit
data
mention
prevent
conclus
infecti
sourc
thu
margin
error
either
way
frequenc
tti
may
appear
less
possibl
even
greater
realli
limit
mathemat
model
donor
data
consid
accur
quantifi
low
risk
transfusiontransmiss
infect
eg
residu
risk
estim
test
monitor
hiv
hcv
hbv
human
lympotroph
viru
htlv
syphili
core
function
surveil
program
blood
center
countri
review
see
tabl
case
rate
firsttim
donor
previous
untest
popul
lower
gener
popul
like
due
partli
donor
select
criteria
exclud
high
risk
donor
partli
due
selfdeferr
donor
blood
program
prepar
estim
risk
potenti
infecti
blood
donat
releas
blood
suppli
tabl
residu
risk
estim
import
evalu
safeti
blood
suppli
use
intern
decis
make
well
physician
counsel
patient
risk
transfus
addit
ongo
analysi
tempor
trend
demograph
markerposit
donat
provid
insight
sourc
risk
chang
test
place
risk
becom
low
measur
recipi
infect
instead
estim
use
mathemat
model
incid
x
window
period
model
origin
describ
sever
studi
unit
state
continu
effort
differ
countri
adapt
improv
model
address
certain
defici
better
address
requir
exampl
uk
addit
window
period
infect
adjust
product
process
error
test
failur
use
routin
although
today
standard
autom
good
manufactur
practic
blood
donat
test
center
test
error
extrem
rare
find
other
revis
methodolog
estim
incid
infect
otherwis
unknown
exampl
mathemat
adjust
unit
state
method
use
nucleid
acid
test
nat
yield
donat
natposit
result
yet
develop
antibodi
propos
substanti
improv
nattest
donat
hiv
hcv
estim
could
includ
firsttim
donor
directli
estim
hepat
b
incid
densiti
problemat
adjust
infect
resolv
donat
thu
directli
detect
requir
origin
propos
unit
state
franc
unit
state
detail
supplement
test
use
improv
identif
incid
hbv
case
includ
hepat
b
surfac
antigen
hbsag
yield
method
work
also
done
address
estim
residu
risk
countri
data
requir
incidencewindow
period
model
fulli
address
blood
program
also
carri
addit
studi
understand
variou
aspect
risk
risk
factor
seroconvert
donor
estim
rate
recent
infect
work
better
understand
risk
donor
test
posit
transmiss
infect
futur
trend
ongo
countri
report
exampl
includ
assess
trend
infect
assess
valu
continu
certain
test
syphili
test
surrog
marker
hiv
assess
risk
current
procedur
place
risk
cytomegaloviru
untest
unit
surveil
play
key
role
assess
need
test
well
evalu
assay
implement
follow
exampl
analys
differ
countri
nucleid
acid
test
expens
technolog
introduc
addit
serolog
screen
reduc
alreadi
low
risk
consequ
evalu
receiv
consider
attent
introduct
uk
estim
expect
frequenc
hcv
natposit
donat
estim
greater
actual
first
year
implement
nat
yield
evalu
unit
state
canada
australia
show
small
gain
confirm
assumpt
nat
yield
case
new
incid
infect
followup
seroconvers
studi
unit
state
australia
show
donor
seroconvert
although
rare
immunolog
silent
infect
would
identifi
nat
indic
valu
nat
test
incid
infect
well
rare
infect
franc
evalu
hivposit
individu
identifi
donor
screen
persist
low
hiv
rna
without
treatment
show
followup
studi
minipool
nat
fail
identifi
nearli
half
sampl
could
reliabl
detect
even
singledon
nat
peopl
posit
test
antibodi
clear
drop
antibodi
assay
could
result
hivposit
donat
enter
blood
suppli
canada
implement
antibodi
hepat
b
core
antigen
test
permit
opportun
investig
potenti
benefit
hbsag
test
alreadi
place
show
x
abbrevi
antihbc
antibodi
hepat
b
core
antigen
expect
rate
roughli
per
unit
intercept
accur
lack
evid
transfus
transmiss
lookback
suggest
infect
recipi
rare
occur
test
htlv
white
cell
leukocyt
associ
viru
implement
countri
implement
univers
leukoreduct
greatli
reduc
risk
transmiss
uk
leukoreduct
introduc
region
studi
suggest
low
preval
donat
peopl
per
year
would
risk
develop
htlvassoci
diseas
transfus
uk
decid
implement
screen
later
develop
pool
system
test
made
test
costeffect
option
introduc
postimplement
evalu
indic
risk
infecti
donat
enter
blood
suppli
reduc
per
million
donat
cours
risk
develop
diseas
would
much
less
initi
analysi
htlv
lookback
data
suggest
leukoreduct
effect
reduc
posttransfus
htlv
studi
assess
safeti
gain
introduct
test
assist
decid
action
need
convers
risk
approach
zero
although
blood
provid
often
find
difficult
reduc
test
initi
implement
identif
lowrisk
reduct
import
justifi
chang
predon
screen
process
may
streamlin
donat
process
countri
method
place
select
donor
lower
risk
transmiss
infect
vs
gener
popul
especi
avoid
window
period
infect
could
go
undetect
test
involv
donor
educ
materi
highrisk
donor
selfdef
predon
questionnair
ask
donor
transmiss
diseas
risk
factor
well
question
exclud
donor
donat
may
advis
health
section
describ
key
system
place
exampl
work
done
assess
effect
process
includ
evalu
risk
factor
donor
test
posit
infecti
agent
monitor
donor
deferr
applic
surveil
data
evalu
predon
screen
process
deferr
criteria
blood
system
countri
system
place
collect
inform
donor
risk
factor
tabl
primari
purpos
ass
donor
select
criteria
intend
reduc
risk
transmiss
diseas
although
limit
identif
risk
factor
rather
evid
caus
method
vari
donor
risk
factor
assess
inperson
interview
counsel
franc
australia
unit
state
canada
telephon
interview
use
uk
method
canada
control
group
also
interview
unit
state
recent
canada
anonym
donor
survey
gener
donor
popul
also
complet
assess
deferr
risk
risk
factor
studi
seroconvert
donor
indic
new
infect
particular
interest
donor
greatest
chanc
miss
test
unit
state
studi
hcv
seroconvert
donor
show
intraven
drug
use
frequent
risk
factor
studi
franc
invas
health
care
procedur
also
associ
suggest
although
much
risk
identifi
current
screen
question
donor
answer
truth
would
still
miss
risk
criteria
often
place
mani
year
data
blood
donor
risk
factor
evalu
screen
criteria
often
better
address
data
model
exampl
potenti
risk
criteria
relat
men
sex
men
evalu
uk
canada
australia
unit
state
approach
countri
vari
attempt
base
model
data
specif
countri
applic
decis
make
recent
hiv
surveil
data
donor
test
risk
factor
analysi
underpin
first
assess
impact
chang
shorten
deferr
men
sex
men
australia
distinct
model
note
previous
first
publish
analysi
use
empir
data
assess
impact
polici
chang
hiv
residu
risk
result
support
conclus
risk
hiv
transmiss
blood
transfus
significantli
impact
australia
consequ
chang
analysi
suggest
rate
complianc
deferr
polici
influenti
overal
risk
durat
deferr
evalu
surveil
data
also
use
assess
donor
screen
process
confidenti
unit
exclus
cue
process
implement
mani
countri
allow
donor
deferr
risk
may
feel
pressur
donat
confidenti
exclud
donat
transfus
studi
unit
state
canada
shown
cue
process
minim
impact
reduc
risk
window
period
infect
least
partli
us
studi
arc
decid
ceas
use
cue
monitor
tti
sinc
shown
advers
effect
chang
chang
donor
select
criteria
method
administr
question
donor
made
creat
opportun
assess
exampl
includ
use
surveil
data
show
shorten
deferr
period
ear
bodi
pierc
tattoo
compromis
safeti
evalu
impact
uniform
donor
histori
questionnair
develop
aabb
task
forc
switch
paperbas
question
facetofac
interview
well
evalu
implement
electron
questionnair
compar
differ
questionnair
format
virus
exist
multipl
genotyp
subtyp
within
infect
individu
virus
hiv
hcv
exist
divers
quasi
speci
genotyp
subtyp
quasi
speci
import
may
vari
infect
limit
detect
assay
may
vari
subtyp
genotyp
thu
monitor
genotyp
within
countri
donor
popul
assist
evalu
risk
import
select
modif
assay
potenti
identifi
mutat
virus
analysi
viral
divers
transmiss
diseas
posit
donor
carri
routin
franc
year
recent
commenc
unit
state
scotland
studi
plan
stage
england
addit
direct
applic
monitor
transfus
safeti
genotyp
permit
insight
origin
infect
differ
genotyp
associ
particular
part
world
genotyp
gener
correl
immigr
pattern
analyz
predict
futur
divers
genotyp
popul
recent
year
sever
new
pathogen
least
new
context
blood
safeti
particular
countri
come
fore
necessit
enhanc
surveil
method
greater
interact
public
health
depart
implement
monitor
safeti
intervent
pathogen
consid
potenti
threat
blood
safeti
either
real
perceiv
activ
approach
gener
adopt
preval
studi
surveil
data
use
risk
assess
turn
form
part
basi
polici
decis
exampl
variou
countri
report
address
surveil
requir
select
emerg
pathogen
discuss
mosquitoborn
viru
describ
africa
seen
north
america
appear
new
york
citi
mark
onset
epidem
spread
across
unit
state
canada
alreadi
compet
popul
mosquito
abl
carri
viru
complet
lifecycl
although
frequent
asymptomat
wnv
potenti
seriou
even
fatal
suscept
host
clear
wnv
could
transmit
transfus
spark
rapid
develop
assay
suitabl
donor
screen
donat
unit
state
canada
test
wnv
unpreced
collabor
fda
key
blood
oper
test
kit
manufactur
countri
public
health
depart
receiv
report
commun
case
includ
local
nation
statist
blood
program
primari
sourc
activ
surveil
logist
reason
test
blood
donat
done
minipool
recognit
minipool
nat
test
could
miss
potenti
infecti
donat
led
develop
test
algorithm
base
minipoolposit
donat
includ
border
blood
center
trigger
individu
donat
nat
test
emerg
wnv
north
america
profound
impact
approach
surveil
unit
state
canada
establish
method
monitor
infect
hiv
hcvhbv
inadequ
realtim
surveil
geograph
indic
need
addit
close
commun
public
health
blood
supplier
necessari
identifi
risk
area
quickli
unit
state
coordin
challeng
larg
mani
independ
blood
center
accustom
work
togeth
level
aabb
develop
web
site
allow
independ
blood
test
laboratori
voluntarili
enter
data
donor
wnvreactiv
case
later
enter
associ
confirmatori
data
permit
close
realtim
monitor
donor
infect
geograph
region
system
combin
network
blood
center
facilit
commun
import
data
blood
center
near
one
anoth
individu
donat
nat
could
trigger
adjac
overlap
area
serv
differ
independ
blood
center
canada
coordin
challeng
less
blood
servic
still
requir
substanti
ingenu
set
monitor
system
visual
map
daili
upload
data
although
blood
supplier
could
monitor
donor
test
data
collect
site
adjac
border
catchment
area
well
border
canada
unit
state
requir
close
commun
facilit
regular
telephon
call
canadian
supplier
us
supplier
public
heath
offici
agreement
provid
urgent
inform
call
unit
state
canada
method
part
routin
wnv
surveil
uk
select
also
call
discretionari
test
wnv
run
season
test
time
commenc
start
end
wnv
season
unit
state
target
travel
endem
area
thu
emerg
wnv
north
america
challeng
key
player
blood
oper
regulatori
bodi
public
health
depart
test
kit
manufactur
work
togeth
rapidli
develop
surveil
methodolog
respons
tactic
alert
transfus
commun
import
strengthen
surveil
new
emerg
threat
chaga
diseas
endem
part
mexico
central
south
america
protozoan
parasit
cruzi
usual
transmit
via
fece
infect
triatomin
insect
vector
often
site
bite
wound
also
transmiss
mother
child
pregnanc
organ
transplant
via
blood
transfus
henc
blood
donat
endem
countri
often
screen
antibodi
cruzi
nonendem
countri
risk
blood
suppli
mainli
immigr
risk
area
data
cruzi
preval
unit
state
come
blood
donor
studi
us
studi
indic
cruzi
antibodi
posit
donor
immigr
risk
area
transfus
transmiss
report
unit
state
canada
suggest
transfus
transmiss
rare
symptom
could
easili
misdiagnos
true
risk
difficult
ascertain
arc
studi
show
donor
select
area
cruzi
antibodi
fda
licens
assay
blood
oper
began
test
donat
cruzi
antibodi
surveil
report
system
similar
use
wnv
set
coordin
aabb
webbas
system
reli
upon
voluntari
report
data
blood
test
laboratori
made
publicli
avail
map
unit
state
posit
donat
shown
regularli
updat
statist
provid
first
nation
preval
data
donor
gener
popul
cruzi
infect
unit
state
addit
studi
done
along
side
implement
assess
risk
factor
cruzi
posit
donor
lookback
studi
assess
frequenc
traceabl
unit
transmit
infect
recent
us
blood
oper
shift
select
test
polici
involv
donor
qualif
test
donor
neg
test
subsequ
donat
need
compar
wnv
situat
unit
state
chaga
diseas
less
urgent
risk
known
mani
year
develop
licens
test
donor
screen
prompt
chang
surveil
requir
addit
unit
state
abl
capit
experi
gain
wnv
use
similar
map
report
system
report
process
well
establish
us
experi
gener
preval
per
donat
screen
first
year
test
howev
lookback
studi
identifi
transfus
transmiss
longterm
us
resid
origin
argentina
among
recipi
blood
confirmedposit
donor
canada
studi
understand
risk
chaga
diseas
blood
suppli
also
conduct
sinc
late
seropreval
studi
complet
major
citi
identifi
posit
donat
among
donor
risk
factor
seri
studi
evalu
potenti
question
use
target
test
canada
move
away
standard
approach
test
donat
select
test
approach
implement
base
partli
lesson
learn
unit
state
mostli
risk
assess
specif
canada
indic
lower
cost
altern
appropri
hq
implement
select
test
identifi
confirmedposit
donat
date
cb
implement
screen
question
identifi
donat
platelet
transfus
plasma
longer
prepar
implement
select
test
may
confirmedposit
donat
date
postimplement
studi
plan
confirm
appropri
select
test
approach
franc
epidemiolog
chaga
diseas
differ
unit
state
canada
french
depart
endem
area
differ
trend
travel
immigr
number
case
gener
popul
french
guiana
increas
immigr
franc
risk
countri
select
test
implement
caribbean
blood
center
although
blood
still
collect
french
guiana
mainland
franc
french
blood
center
caribbean
mainland
franc
donor
select
test
donor
mother
born
latin
america
donor
travel
risk
area
travel
defer
first
month
return
first
month
test
pari
region
popular
destin
immigr
franc
confirmedposit
donor
identifi
test
donor
indic
small
real
potenti
risk
avert
uk
select
test
implement
donor
born
whose
mother
born
south
america
irrespect
time
sinc
resid
andor
birth
addit
peopl
live
work
rural
area
south
central
america
continu
period
week
defer
month
test
infect
identifi
sinc
select
test
introduc
countri
australia
test
implement
perceiv
risk
low
record
case
transfus
transmiss
autochthon
case
report
immigr
south
america
compar
low
risk
minim
restrict
donor
born
transfus
south
america
donat
plasma
fraction
condit
suspect
tti
report
blood
supplier
main
form
surveil
first
recogn
novel
neurolog
diseas
cattl
bovin
spongiform
encephalopathi
attribut
infect
sheep
cattl
offal
fed
cattl
uk
earli
thousand
cattl
diagnos
million
inciner
new
neurolog
diseas
alway
fatal
report
human
new
variant
creutzfeldtjakob
diseas
cjd
presum
caus
consumpt
bovin
spongiform
encephalopathyinfect
meat
transplant
organstissu
infect
donor
uk
experienc
largest
epidem
variant
cjd
vcjd
franc
next
affect
case
countri
although
transfus
transmiss
initi
consid
improb
view
reconsid
light
experiment
evid
wider
distribut
infect
agent
prion
within
patient
classic
cjd
eventu
document
transfusiontransmit
clinic
case
nation
surveil
cjd
case
establish
uk
nation
cjd
surveil
unit
case
medic
histori
famili
member
consult
determin
histori
blood
transfus
donat
collabor
studi
uk
transfus
servic
transfus
medicin
epidemiolog
review
establish
date
identifi
patient
vcjd
receiv
blood
product
consid
probabl
tti
result
clinic
vcjd
recipi
report
suspect
vcjd
transmiss
differ
infect
reli
close
work
health
protect
author
hpa
blood
servic
nation
vcjd
surveil
unit
date
confirm
tti
case
among
small
group
recipi
activ
surveil
receiv
blood
compon
donor
later
develop
vcjd
test
suitabl
blood
donor
develop
surveil
program
expand
includ
surveil
test
infect
detect
sever
precautionari
measur
introduc
uk
includ
donor
select
eg
exclus
donor
receiv
blood
transfus
sinc
import
plasma
use
product
manufactur
blood
leukoreduct
malaria
endem
countri
report
ongo
risk
import
malaria
far
greatest
risk
socal
semiimmun
donor
born
resid
malariaendem
countri
particularli
subsaharan
africa
papua
new
guinea
domin
speci
plasmodium
falciparum
lethal
speci
infect
human
potenti
risk
transfus
transmiss
vari
immigr
polici
travel
prefer
countri
popul
base
popul
rate
import
malaria
case
associ
travel
toresid
world
health
organizationdefin
highrisk
countri
franc
uk
greatest
risk
semiimmun
donor
howev
inclus
lowrisk
travel
differ
countri
assess
atrisk
donor
percentag
donor
classif
vari
australia
franc
canada
unit
state
surveil
approach
similar
countri
monitor
commun
case
tti
polici
vari
franc
uk
australia
appli
select
test
polici
rapidli
reinstat
healthi
donor
countri
also
therefor
monitor
infect
atrisk
donor
unit
state
canada
appli
deferr
criteria
without
option
test
current
test
identifi
antibodi
p
falciparum
speci
high
sensit
rare
transfusiontransmit
case
malaria
identifi
uk
franc
relat
failur
test
rather
test
failur
franc
evalu
tti
occur
select
test
place
prompt
revis
polici
reduc
risk
postimplement
evalu
australia
show
test
greatli
reduc
impact
deferr
recoveri
annual
product
red
blood
cell
platelet
importantli
achiev
without
appar
chang
risk
transfusiontransmit
malaria
overal
malaria
antibodi
test
strategi
franc
uk
australia
highli
effect
howev
case
delay
onset
relaps
p
vivax
malaria
australian
donor
highlight
previous
unreport
limit
strategi
p
vivax
abl
sequest
liver
month
sever
year
reemerg
caus
clinic
malaria
importantli
antibodi
test
matter
laboratori
malaria
test
unabl
identifi
donor
potenti
risk
relaps
highlight
implic
donor
test
antibodi
neg
subsequ
recent
travel
papua
new
guinea
countri
along
neighbor
carri
much
greater
risk
relaps
fortun
compon
donor
transfus
rariti
make
impact
recipi
safeti
neglig
compar
risk
semiimmun
donor
nonetheless
ab
alreadi
move
close
gap
implement
restrict
plasma
fraction
within
test
embargo
donor
return
papua
new
guinea
unit
state
canada
risk
malaria
manag
deferr
travel
toresid
endem
area
donor
histori
malaria
passiv
surveil
data
avail
effort
surveil
focus
impact
deferr
countri
dengu
virus
mosquito
born
similar
wnv
flavivirus
carri
shortterm
period
viremia
day
although
patient
recov
primari
dengu
infect
primari
commonli
secondari
infect
fatal
nearli
two
third
infect
asymptomat
symptom
occur
usual
notic
within
day
case
transfus
transmiss
document
believ
may
common
outbreak
difficult
distinguish
transfusiontransmit
case
vector
transmiss
shortterm
infect
dengu
attract
lesser
attent
transfus
surveil
countri
outbreak
occur
canada
franc
uk
howev
mosquito
vector
dengu
resid
part
countri
reportnorthern
australia
southern
unit
state
puerto
rico
endem
investig
nat
assay
donor
screen
develop
dengu
viru
serotyp
test
donor
outbreak
hondura
brazil
australia
show
viremia
present
low
percentag
asymptomat
donor
puerto
rico
arc
largest
singl
provid
blood
dengu
endem
year
round
annual
islandwid
outbreak
dengu
branch
cdc
locat
san
juan
conduct
ongo
surveil
dengu
puerto
rico
outbreak
nat
use
genprob
transcriptionmedi
amplif
assay
perform
retrospect
period
assess
frequenc
donor
viremia
total
donat
posit
donat
infecti
viru
recov
donat
may
abl
transmit
infect
indic
risk
transfus
transmiss
larger
outbreak
higher
rate
donor
viremia
document
along
transfusiontransmit
case
manag
risk
includ
implement
predon
question
regard
denguelik
symptom
use
enhanc
postdon
inform
sheet
encourag
donor
call
back
denguelik
symptom
develop
infect
donor
defer
day
dengu
diagnosi
onset
ill
whichev
later
dengu
viru
ag
test
biorad
pari
franc
initi
march
shortli
new
outbreak
declar
donor
screen
assay
target
dengu
viru
rna
would
prefer
avail
signific
fund
requir
commerci
apart
puerto
rico
nearli
dengu
case
report
us
continent
state
acquir
elsewher
travel
immigr
last
report
continent
dengu
outbreak
south
texa
key
west
florida
sever
autochthon
case
report
counti
mainland
florida
small
dengu
outbreak
occur
hawaii
australia
dengu
endem
season
outbreak
believ
occur
travel
infect
oversea
arriv
local
transmiss
cycl
establish
risk
blood
suppli
manag
implement
supplement
donor
select
measur
activ
outbreak
addit
question
ad
donor
questionnair
identifi
donor
travel
resid
outbreak
area
donor
may
donat
plasma
fraction
outbreak
period
restrict
remain
place
month
last
case
onset
date
better
understand
quantifi
transmiss
risk
associ
blood
collect
outbreak
model
origin
develop
wnv
adapt
base
known
case
subclin
infect
small
outbreak
model
predict
low
risk
transfus
transmiss
outbreak
overal
vari
predict
incid
period
peak
high
dengu
appear
present
low
risk
transfus
transmiss
even
endem
area
experi
vectorborn
diseas
malaria
especi
wnv
rapid
widespread
infect
north
america
may
sensit
transfus
industri
type
potenti
risk
surveil
activ
therefor
direct
monitor
possibl
outbreak
respons
plan
also
develop
understand
transmiss
potenti
develop
test
gain
experi
assay
suitabl
donor
screen
babesiosi
tickborn
diseas
endem
rel
small
region
unit
state
northeastern
upper
midwestern
red
cellassoci
protozoan
parasit
transmit
bite
infect
tick
typic
result
either
mild
symptom
resolv
within
week
asymptomat
also
transmit
transfus
caus
sever
even
fatal
diseas
recipi
addit
endem
area
tick
appear
gradual
increas
donor
often
unawar
infect
screen
question
like
identifi
risk
donor
seropreval
studi
done
assess
risk
assist
develop
strategi
risk
reduct
transfusiontransmit
case
monitor
minimum
transfusiontransmit
case
unit
state
last
year
surveil
babesia
shown
pose
risk
us
blood
suppli
accept
solut
yet
identifi
test
donor
would
address
problem
yield
would
extrem
low
costeffect
time
test
donor
endem
region
may
feasibl
miss
posit
donat
travel
endem
region
henc
combin
test
donor
atrisk
area
select
test
donor
may
travel
risk
area
may
possibl
like
low
yield
donor
especi
travel
contact
vector
tick
intervent
test
endem
area
unit
state
begin
investig
implement
data
studi
drive
polici
develop
canada
babesia
report
surveil
approach
much
lower
key
activ
surveil
popul
vector
tick
near
endem
region
unit
state
possibl
babesia
infect
may
occur
canada
may
occur
futur
habitat
tick
expand
seropreval
studi
consid
date
surveil
canada
focus
survey
estim
donor
risk
travel
monitor
public
health
data
note
tti
donor
travel
unit
state
chikungunya
viru
mosquitoborn
agent
first
describ
year
ago
caus
mani
outbreak
africa
asia
symptom
includ
fever
joint
muscl
pain
headach
last
day
sometim
longer
also
asymptomat
although
blood
transmiss
document
theoret
possibl
small
outbreak
chikungunya
viru
occur
french
island
reunion
island
near
madagascar
indian
ocean
much
larger
epidem
largest
ever
record
case
continu
outbreak
reunion
island
requir
immedi
coordin
effort
part
public
health
offici
blood
servic
red
cell
plasma
could
transport
continent
franc
shorter
shelf
life
platelet
unit
still
need
produc
local
pathogen
reduct
system
quickli
implement
march
shortli
suspend
collect
red
cell
plasma
collabor
group
compos
member
agenc
de
sanitair
de
produit
de
french
regul
ef
int
coordin
inv
estim
risk
viremia
blood
donat
outbreak
use
public
health
surveil
data
ramp
epidem
appli
methodolog
gain
wnv
outbreak
unit
state
risk
estim
made
small
outbreak
predict
use
case
report
decemb
use
make
decis
stop
collect
red
cell
plasma
januari
peak
epidem
later
risk
estim
use
recomm
blood
collect
confirm
test
data
platelet
collect
addit
base
estim
donat
expect
virem
stop
collect
transfusiontransmit
case
report
sever
influenza
pandem
past
sudden
appear
rapid
movement
anoth
diseas
sever
acut
respiratori
syndrom
concern
mutat
influenza
virus
could
spread
person
person
postul
avian
influenza
result
pandem
made
mark
public
health
plan
transfus
servic
comprehens
pandem
plan
norm
influenza
short
phase
viremia
risk
transfus
transmiss
like
small
zero
howev
pandem
situat
potenti
disrupt
blood
suppli
donor
ill
decreas
attend
collect
site
staff
ill
neg
impact
process
blood
unit
well
peopledepend
process
transport
pandem
plan
therefor
focu
type
issu
includ
estim
product
requir
may
reduc
pandem
plan
staff
redeploy
vaccin
avail
prophylact
treatment
staff
altern
current
process
plan
also
involv
interact
public
health
agreement
prioriti
statu
treatment
staff
patient
comparison
blood
system
industri
countri
contin
show
fairli
uniform
rang
transfus
surveil
activ
tabl
key
area
focu
surveil
classic
pathogen
hiv
hcv
hbv
surveil
new
emerg
pathogen
local
intern
import
key
factor
influenc
precis
natur
activ
structur
blood
program
surveil
system
strateg
focu
blood
program
epidemiolog
diseas
countri
although
test
pathogen
hiv
hbv
hcv
result
vanishingli
small
residu
risk
surveil
relat
pathogen
high
prioriti
public
expect
zero
risk
pressur
still
exist
ongo
focu
current
polici
often
relat
assess
potenti
simplif
process
rather
necessarili
address
risk
multipl
layer
donor
test
donor
deferr
polici
implement
year
high
impact
oper
effici
cost
blood
product
reevalu
necessari
individu
combin
contribut
safeti
alway
clear
time
implement
may
chang
epidemiolog
diseas
chang
gener
popul
part
evalu
safeti
surveil
viral
divers
need
assess
perform
screen
assay
emerg
new
infecti
diseas
instig
substanti
growth
surveil
activ
test
readi
address
new
threat
emerg
hiv
late
profound
effect
transfus
industri
key
factor
recognit
surveil
system
specif
blood
transfus
essenti
result
improv
structur
surveil
although
tend
focu
risk
base
sexual
activ
inject
drug
use
emerg
infect
sinc
differ
transmiss
pathway
arthopod
vector
food
chain
emerg
pathogen
challeng
blood
program
draw
upon
resourc
avail
rapid
effect
respons
result
develop
surveil
methodolog
respons
plan
recognit
origin
focu
risk
reduct
sexualdrugrel
risk
hiv
hepat
left
larg
gap
prevent
measur
exampl
emerg
wnv
north
america
recognit
transfus
transmiss
demonstr
quickli
emerg
pathogen
could
becom
seriou
transfus
risk
highlight
inadequaci
current
surveil
system
unit
state
rapid
develop
nation
surveil
system
wnv
serv
basi
develop
surveil
cruzi
antibodyposit
donor
highlight
need
ongo
interact
blood
servic
public
health
agenc
select
test
reduc
risk
import
pathogen
univers
test
may
inappropri
exampl
includ
select
test
cruzi
uk
canada
unit
state
propos
strategi
consider
australia
well
select
test
polici
malaria
uk
franc
australia
arc
alreadi
commenc
select
dengu
test
puerto
rico
australia
current
undertak
costbenefit
analysi
assess
similar
strategi
minim
compon
loss
season
outbreak
similarli
outbreak
wnv
itali
increas
incid
west
nile
neuroinvas
diseas
prompt
concern
donor
return
australia
countri
outbreak
period
pose
increas
risk
outbreak
greec
russia
demonstr
similarli
increas
virul
ab
institut
restrict
plasma
fraction
donor
return
defin
outbreak
region
expans
wnv
europ
continu
target
wnv
nat
may
costeffect
compon
restrict
therefor
may
consid
altern
strategi
australia
countri
fewer
blood
supplier
formal
relationship
public
health
well
situat
address
risk
countri
without
advantag
effect
surveil
appear
similar
collabor
arrang
develop
larg
specif
purpos
reli
upon
initi
continu
effort
transfus
commun
maintain
transfus
surveillancepubl
health
interact
also
potenti
benefit
commun
health
activ
surveil
infect
knowledg
risk
factor
infect
healthi
lowrisk
popul
overal
transfus
surveil
tend
rather
underus
resourc
area
greater
collabor
effort
public
health
transfus
surveil
potenti
make
better
use
personnel
resourc
improv
aspect
surveil
may
logic
futur
direct
examin
evolut
surveil
program
differ
blood
program
differ
countri
suggest
futur
trend
may
includ
continu
improv
emphasi
nation
surveil
greater
emphasi
mutual
benefici
public
health
interact
intern
collabor
countri
face
similar
compet
pressur
intens
public
desir
thing
necessari
reduc
risk
measur
vanishingli
small
risk
infect
blood
suppli
manag
blood
suppli
costeffici
manner
accordingli
continu
reassess
current
safeti
polici
well
risk
assess
new
pathogen
increas
profil
surveil
program
appli
scientif
principl
identifi
option
accept
safeti
standard
excess
make
better
use
finit
health
care
resourc
